semaglutide biosimilar (Zhuhai United Laboratories)

N/A

Report date: 2025/03/20 20:00:06

Base Information

Drug Namesemaglutide biosimilar (Zhuhai United Laboratories)
Drug Alias NameN/A
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant polypeptide
Mechanisms of ActionGlucagon-like peptide 1 receptor agonists
TargetsGlucagon-like peptide 1 receptor
Therapy Area/IndicationsObesityDiabetes Mellitus, Type 2Alzheimer Disease +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaPhase 1 Clinical
Originator CompaniesZhuhai United Laboratories Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesZhuhai United Laboratories Co Ltd
Inactive CompaniesN/A
Active IndicationsObesityDiabetes Mellitus, Type 2Alzheimer Disease +[4] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A